NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

NewAmsterdam Pharma Company N.V. (NAMS) Stock Analysis

NewAmsterdam Pharma Company N.V. (NAMS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

NAMS

$21.49

−$0.01 (−0.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NAMS with… →

NAMS Key Statistics

As of Oct 21, 2026
Trading
Open
$21.58
Previous Close
$21.50
Day's Range
21.31–22.28
52-Week Range
19.58–42.21
Volume
1.25M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.10
Valuation
Market Cap
$2.51B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
352.80
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.16
Financials (FY)
Revenue (FY)
$22.50M−50.61%
Net Income (FY)
−$203.82M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
116.90M
1-Year Return
−41.09%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.39M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, NAMS closed at $21.49, −41.09% over 1 year.

NewAmsterdam Pharma Company N.V. (NAMS) has a market capitalization of $2.51B.

In fiscal 2025, NAMS reported revenue of $22.50M.

NAMS Stock Return by Calendar Year

NewAmsterdam Pharma Company N.V. (NAMS) return since Feb 2021: what $10,000 became

1 year
$10,000 $5,891
−41.09%
5 years
$10,000 $21,973
+119.73%
Since Feb 2021
$10,000 $20,251
+102.51%

If you had invested $10,000 in NewAmsterdam Pharma Company N.V. (NAMS) at the close on February 9, 2021, the earliest close on record here, it would have been worth $20,251 at the close on October 21, 2026: +102.51% in total, +13.19% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−38.74%
2025+36.50%
2024+130.08%
2023+2.48%
2022+11.79%
2021 (partial year)−8.12%

As of October 21, 2026.

NAMS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$22.50M−$203.82M−905.7%
2024$45.56M−$241.60M−530.3%
2023$14.09M−$176.94M−1,255.8%
2022$102.69M−$22.63M−22.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$22.50M—−$225.68M−$203.82M−905.7%
2024$45.56M—−$176.29M−$241.60M−530.3%
2023$14.09M—−$182.97M−$176.94M−1,255.8%
2022$102.69M—−$3.56M−$22.63M−22.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NAMS Valuation vs Biotechnology Median

Median of 608 stocks
MetricNAMSBiotechnology medianvs median
P/S ratio352.8013.3026.5x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

NewAmsterdam Pharma Company N.V. (NAMS) carries a market capitalisation of $2.51B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 100.

NAMS last closed at $21.49 on October 21, 2026. That is −$0.01 (−0.05%) against the previous close. The 52-week range on file runs from $19.58 to $42.21. The latest close sits 9.75% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $22.50M. That is −50.61% against the prior fiscal year, when revenue was $45.56M. The same year closed with a net loss of $203.82M. Earnings per share on a trailing basis come to −2.16.

Across the 4 fiscal years on file, revenue moves from $102.69M in 2022 to $22.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 352.8 times revenue. On price-to-sales that is 26.5 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −41.09%. Measured over 5 years, that is +17.05% a year compounded. Beta against the wider market is reported at 0.1. Daily returns over the trailing 5 years annualize to a volatility of 61.79%.

Growth & Income

The record shows no dividend for NAMS.

The strongest complete calendar year on file is 2024 at +130.08%; the weakest is 2023 at +2.48%. Of the 4 complete calendar years on file, 4 finished higher. So far in 2026 the total return is −38.74%.

Peer Comparison

NewAmsterdam Pharma Company N.V. (NAMS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
NewAmsterdam Pharma Company N.V. NAMS $2.51B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. NewAmsterdam Pharma Company N.V. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Visit website →